Amgen Inc. (NASDAQ:AMGN) Announces Quarterly Dividend of $2.52

Amgen Inc. (NASDAQ:AMGN) announced a quarterly dividend on Thursday, July 30th. Investors of record on Friday, August 21st will be paid a dividend of 2.52 per share by the medical research company on Friday, September 11th. This represents a c) annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Friday, August 21st.

Amgen has increased its dividend payment by an average of 0.1%per year over the last three years and has increased its dividend every year for the last 14 years. Amgen has a dividend payout ratio of 46.8% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Amgen to earn $23.86 per share next year, which means the company should continue to be able to cover its $10.08 annual dividend with an expected future payout ratio of 42.2%.

Amgen Price Performance

Amgen stock opened at $387.64 on Friday. The stock’s fifty day simple moving average is $355.69 and its 200-day simple moving average is $353.55. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The firm has a market capitalization of $209.21 billion, a P/E ratio of 26.98, a P/E/G ratio of 3.92 and a beta of 0.41. Amgen has a twelve month low of $269.77 and a twelve month high of $398.00.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the previous year, the firm posted $4.90 earnings per share. The company’s revenue was up 5.8% compared to the same quarter last year. As a group, equities analysts expect that Amgen will post 22.31 earnings per share for the current fiscal year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.